The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia
about
Animal models of prenatal immune challenge and their contribution to the study of schizophrenia: a systematic review.Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study.The improved Clinical Global Impression Scale (iCGI): development and validation in depressionThe impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample.Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) studyDental conditions in inpatients with schizophrenia: a large-scale multi-site survey.Disability and schizophrenia: a systematic review of experienced psychosocial difficulties.Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.Collaborative community based care for people and their families living with schizophrenia in India: protocol for a randomised controlled trial.A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia.Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA studyCriteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders.Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders.The impact of antipsychotic polytherapy costs in the public health care in Sao Paulo, BrazilRelationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study.Counterfactual Reasoning Deficits in Schizophrenia Patients.Assessing the impact on caregivers of patients with schizophrenia: psychometric validation of the Schizophrenia Caregiver Questionnaire (SCQ).Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy.Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms.Patients with schizophrenia activate behavioural intentions facilitated by counterfactual reasoning.Lay health supporters aided by a mobile phone messaging system to improve care of villagers with schizophrenia in Liuyang, China: protocol for a randomised control trialProtocol for the development and validation of a questionnaire to assess concerning behaviours and mental health in individuals with autism spectrum disorders: the Assessment of Concerning Behaviour (ACB) scale.Needs-oriented discharge planning and monitoring for high utilisers of psychiatric services (NODPAM): design and methodsOverview of the findings from the European SOHO study.Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?The neuropsychology of the schizo-obsessive subtype of schizophrenia: a new analysis.Implementing routine outcome measurement in psychiatric rehabilitation services in Israel.Differences in cognitive function and daily living skills between early- and late-stage schizophrenia.Using Routine Outcome Measures to Provide Feedback at the Service Agency Level.Severity of illness and extra pyramidal symptoms as predictors for oral diseases among patients with schizophrenia.White-matter connectivity related to paliperidone treatment response in patients with schizophrenia.Early detection and integrated care for adolescents and young adults with psychotic disorders: the ACCESS III study.Early detection and integrated care for adolescents and young adults with severe psychotic disorders: rationales and design of the Integrated Care in Early Psychosis Study (ACCESS III).Neuropsychological Profile of Specific Executive Dysfunctions in Patients with Deficit and Non-deficit Schizophrenia.Transdiagnostic Clinical Global Impression Scoring for Routine Clinical SettingsPeripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia.Subjective experience and meaning of psychoses: the German Subjective Sense in Psychosis Questionnaire (SUSE).Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study.
P2860
Q30445744-857B4B22-E12C-48F9-9839-671660E4721BQ31043571-DD08D430-BD45-41FA-9BC3-6666ABA827C0Q33272500-6E9784C8-7B66-45FF-A3A8-0B5BAEDA14EBQ33641039-42464218-8DBA-4E05-8A8C-82312929A8A2Q34343697-0ABD53F1-5343-46D6-A877-9D5F44D0C18EQ34383365-3514486D-119A-4BF7-9FF5-E0FE2FDD86BFQ34471145-35071989-A4E3-4BC3-B5E5-987F9194B16EQ34498541-8E9A2734-FB03-4399-A930-2EAEACF178E5Q34552704-0001876B-3A97-4B6A-A669-1799EA4782DBQ34590496-23F3527C-62D0-4658-8E06-2A0A31F7C07BQ34632976-F800BE3A-15F8-47BE-AC59-7BC0B7E54082Q35057412-6B2206C0-ED40-48F2-BDA1-9970EF58BD98Q35096476-A81025C6-48C5-451D-B28D-73721494D773Q35324015-CBC5EF12-B14D-49C9-AE61-114135EC7F7BQ35736374-06996952-34F8-4243-BFAA-6FE386C595DCQ35909644-CD3B23D3-28DC-482E-8E73-2FB51C206141Q36081036-AD39876F-5114-4AA7-921C-54FFAF1D3D8FQ36234891-9B54F49F-644C-443C-9764-F042ABCBA9DBQ36371727-E1730CDB-3B7A-490A-A048-3DA50A43757FQ36394072-78C2BF9D-21FA-44D7-BD80-E7163F18C611Q36526847-11F02DAF-4D7D-40A5-A12A-962347BA7EB5Q36732851-93652F18-87E2-47A8-BEB8-7022322863B7Q36803253-B81ABD7A-8F28-4CBE-8386-75752F76A164Q37174029-5DF94ECA-0826-4E0B-AE50-03848F19B445Q37886136-07162640-C488-492A-A9D6-C4BBDFC0CE78Q38016230-15B57327-1C91-4111-9805-45519BE452AAQ38378431-C7275215-DE0D-4FD4-AB21-88BBFAD44531Q38390793-021D6345-101C-4EA8-B744-6DF902041709Q38422220-B9F856CE-2A06-4E18-B0CC-F6CACD1A9DECQ38850541-8CDFC7F1-3441-45C0-9F00-52908BB03F5BQ39002654-89C94EA2-0D52-4C41-92D1-2979563B5A5DQ40119382-BEC26693-E1DD-45B7-9457-5247143E37E2Q40169692-B7E07104-4093-42B4-9014-9991E5959555Q40585562-013DA0FA-0E3A-41B7-B21B-474DC76C33E5Q41600823-44073180-7BC1-45B4-B1D4-76DC39B1D212Q41663038-04D12048-69B6-43A7-8234-60DDF6AA2121Q42084606-78A89412-E912-47F7-A4B9-8088D927EC98Q43427642-65B3F222-ED38-4CAF-8D47-F838BA28EF7CQ44228933-D18E8131-C07F-4F54-8571-F3C9EA0DA30BQ44317309-3F1A2C93-CCDC-436E-B118-DD5E993728EA
P2860
The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia
description
scientific article published on 01 January 2003
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2003
@uk
name
The Clinical Global Impression ...... ptoms present in schizophrenia
@en
The Clinical Global Impression ...... ptoms present in schizophrenia
@nl
type
label
The Clinical Global Impression ...... ptoms present in schizophrenia
@en
The Clinical Global Impression ...... ptoms present in schizophrenia
@nl
prefLabel
The Clinical Global Impression ...... ptoms present in schizophrenia
@en
The Clinical Global Impression ...... ptoms present in schizophrenia
@nl
P2093
P2860
P1476
The Clinical Global Impression ...... ptoms present in schizophrenia
@en
P2093
A Kharbeng
E Lavrentzou
P2860
P356
10.1034/J.1600-0447.107.S416.5.X
P407
P577
2003-01-01T00:00:00Z